Alpha Tau Medical - DRTS Net Assets per Single Share

The financial price action for Alpha Tau Medical Ltd. (DRTS) illustrates the dynamics of a company optimizing isotope delivery for precision alpha therapy and securing high margins through logistics control. The Israeli business is implementing advanced radiation exposure methods, confirming efficacy across global clinics. Technological superiority and FDA patents create an insurmountable barrier to entry for competitors, while the current metric stands at 0.48.

Investors must evaluate the intrinsic value of Alpha Tau Medical Ltd. (DRTS) by determining the gap between the market price and actual equity. Analyzing the bps metric, which currently stands at 0.48, we see net assets minus liabilities, confirming the company's stability through the outsourcing of component production to external partners while maintaining control over key radiation technologies.